The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in
November 2019, quickly spread around the world becoming a pandemic. Despite the …

An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first reported in Wuhan, China in December 2019. An extremely high potential for …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Here we report on the most recent updates on experimental drugs successfully employed in
the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID …

Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only
antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 …

Background: The spread of COVID-19 has become a growing cause of mortalities over the
globe since its major outbreak in December 2019. The scientific and medical communities …

The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has
now become a pandemic with no approved therapeutic agent. At the moment, the genomic …

Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …

Coronaviruses are a large group of viruses known to cause illnesses that vary between the
common cold and more severe diseases to include severe acute respiratory syndrome …

On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …